title: Elicitation of bovine antibody to BLV-gp51 by BLV-vaccination.
abstract: This study was carried out to demonstrate sequential changes of antibody response to gp51 of BLV in bovine hosts injected with BLV-vaccine. BLV vaccine was prepared from culture fluids from FLK-BLV cells by treatment with 0.1% formalin for 48 hrs at 4 degrees C followed by ultrafiltration and lyophilization. Sterile vaccine containing 300 mg protein/ml, 1 mg of which was reactive by ELISA with monoclonal anti-BLV-glycopeptide up to 1:256 dilution, was injected intradermally with Freund's adjuvant into two 1-month-old Holstein calves seronegative for BLV. The first and second booster injections were given without adjuvant 3 and 15 weeks, respectively, after the initial injection. Sera collected weekly from these animals were analyzed to monitor development of antibody to BLV-gp51 by Western blotting and immunoferritin electron microscopy, as well as by ELISA to whole BLV and to BLV-gp51 partially purified by column chromatography. Antibody to BLV-gp51 was detected in sera collected 2 weeks after the initial injection, increased 2 weeks after the first booster, maintained its level during the following 10 weeks, and increased again 2 weeks after the second booster injection. Infectious BLV was not detected by syncytium-formation assay of lymphocytes collected 15 weeks after the initial injection. This study demonstrated sequential changes of anti-BLV-gp51 antibody elicited in bovine hosts subsequent to injection of formalin-treated BLV. Further analysis of bovine antibody to BLV-gp51 may help develop improved BLV-vaccine.
authors.affiliation: Chiba Cancer Center Research Institute, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Maruyama
authors.forename: T
authors.initials: T
authors.lastname: Fukushima
authors.forename: S
authors.initials: S
authors.lastname: Mochizuki
authors.forename: H
authors.initials: H
authors.lastname: Abe
authors.forename: M
authors.initials: M
authors.lastname: Onuma
authors.forename: A
authors.initials: A
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Misawa
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000956:Antigens, Viral / Q000276:immunology*; D015153:Blotting, Western; D002417:Cattle / Q000276:immunology*; D002459:Cell Fusion; D004797:Enzyme-Linked Immunosorbent Assay; D005557:Formaldehyde; D006023:Glycoproteins / Q000276:immunology; D001909:Leukemia Virus, Bovine / Q000276:immunology* / Q000502:physiology; D012190:Retroviridae / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; D005557:Formaldehyde